AstraZeneca


BERG is partnering with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.

Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central nervous system (CNS) optimized fragments to assist BERG in the discovery of candidates for therapeutic development.